Navigation Links
New Stem Cell Technology to Improve Drug Safety
Date:4/22/2009

TOKYO, April 22 /PRNewswire-Asia/ -- Drug side effects are a major problem for the drug industry. Even very rare events, if serious enough, can warrant drug withdrawal. Unfortunately, these problems often emerge only after a drug has been used by thousands or even millions of patients.

Identifying drugs that can trigger heart attacks before they reach the clinic is a major focus of ReproCELL. Current cardiotoxicity tests, especially at early stages of drug development, tend to focus on one aspect of heart cell function -- the hERG ion channel. But there are a whole range of other ion channels, as well as other possible issues, which hERG tests miss. ReproCELL has developed the QTempo assay to comprehensively screen cardiac ion channels and other factors to significantly reduce the chances of a cardiotoxic drug reaching the clinic.

The QTempo test uses beating heart cells grown in a dish from stem cells. Similar to an ECG, these cells are attached to electrodes to measure their electrical activity, which is monitored as experimental drugs are added. Until recently, ethical issues surrounding human embryonic stem cells, had restricted QTempo to monkey heart cells. Now, under a license agreement between ReproCELL and iPS Academia, a human version of this new test is available. This is the first ever commercial test using iPS technology.

ReproCELL's CEO, Chikafumi Yokoyama, commented "Drug companies usually prefer to see in-vitro data from human cells. Basing the QTempo assay around human heart cells makes the test more clinically relevant. Not only will the improved test contribute to patient safety, it will help reduce the huge amounts of effort drug companies waste on developing drugs that are later withdrawn".

iPS Academia, KYOTO, JAPAN, was established to license iPS technology developed in the Kyoto lab of Shinya Yamanaka. The iPS (induced Pluripotent stem cell) technology is a revolutionary new way of making embryonic-like stem cells from normal adult tissue, typically skin cells.

ReproCELL, TOKYO, JAPAN, offers stem cell-focused products and services to researchers and health professionals. ReproCELL products are used in many of the world's leading stem cell labs and were used in the development of the world's first human iPS cells. ReproCELL has applied its stem cell expertise to develop pre-clinical and clinical diagnostic tests to improve the development of drugs and monitoring of patients.

For further information, please visit http://www.reprocell.net .


'/>"/>
SOURCE ReproCELL Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quantum light beams good for fast technology
2. New Smart Technology Makes Patient Data Collection Easier, More Efficient
3. Align Technology Executive to Present at Upcoming Financial Conferences
4. Pioneer Surgical Technology Hires Vice President of New Business Development
5. Purdue researchers develop technology to detect cancer by scanning surface veins
6. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
7. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
9. Stevens Health, Technology and Society roundtable: Sept. 19
10. Microbiotic technology developed for microinjection of zebrafish embryos
11. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids ... Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, ... run is geared towards children of all ages; it is a non-competitive, non-timed event, ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/4/2017)... , Oct. 4, 2017 ... single-use, self-contained, illuminating medical devices, today announced regulatory ... Health Surveillance Agency (or Agência Nacional de Vigilância ... first single-use, cordless surgical retractor with integrated LED ... optimal access, illumination and exposure of a tissue ...
(Date:10/2/2017)... Oct. 2, 2017  AllianceRx Walgreens Prime, the combined ... Walgreens and pharmacy benefit manager Prime Therapeutics LLC (Prime), ... which included the unveiling of new signage at its ... well as at a few other company-owned facilities across ... to patients, some of whom will begin to see ...
Breaking Medicine Technology: